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Background: A prolonged-release formulation of oxycodone/naloxone has been shown to be effective in European populations 
for the management of chronic moderate to severe pain. However, no clinical data exist for its use in Korean patients. The objec-
tive of this study was to assess efficacy and safety of prolonged-release oxycodone/naloxone in Korean patients for management 
of chronic moderate-to-severe pain.
Methods: In this multicenter, single-arm, open-label, phase IV study, Korean adults with moderate-to-severe spinal disorder-
related pain that was not satisfactorily controlled with weak opioids and nonsteroidal anti-inflammatory drugs received prolonged-
release oral oxycodone/naloxone at a starting dose of 10/5 mg/day (maximum 80/40 mg/day) for 8 weeks. Changes in pain 
intensity and quality of life (QoL) were measured using a numeric rating scale (NRS, 0–10) and the Korean-language EuroQol-five 
dimensions questionnaire, respectively.
Results: Among 209 patients assessed for efficacy, the mean NRS pain score was reduced by 25.9% between baseline and week 
8 of treatment (p < 0.0001). There was also a significant improvement in QoL from baseline to week 8 (p < 0.0001). The incidence 
of adverse drug reactions was 27.7%, the most common being nausea, constipation, and dizziness; 77.9% of these adverse drug 
reactions had resolved or were resolving at the end of the study. 
Conclusions: Prolonged-release oxycodone/naloxone provided significant and clinically relevant reductions in pain intensity and 
improved QoL in Korean patients with chronic spinal disorders. (ClinicalTrials.gov identifier: NCT01811238)
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Chronic pain related to spinal disorders is a common and 
important clinical issue in many adult populations.1,2) A 
nationally-representative Korean survey conducted in 
2007 estimated that over 5.5 million Korean adults had 
ever experienced back pain (around 15% of those aged 
20–89 years); furthermore, an estimated 37% of these indi-
viduals suffered from chronic back pain (> 3 months’ du-
ration).3) In a cross-sectional study of patients undergoing 
computed tomography scans for issues unrelated to spinal 
disorders, approximately 36% of patients reported back 
pain lasting for at least 1 month.4) 
Adequate management of chronic pain is impor-
tant to reduce its impact on many aspects of daily living, 
including work activity, sleep, mood, and quality of life 
(QoL).5-7) There is evidence showing that individuals who 
achieve good pain control benefit substantially in terms of 
improved work activity, functioning, and QoL, and experi-
ence less depression and fatigue.5)
Nonopioid analgesics are usually the first treat-
ment option for mild to moderate chronic non-cancer 
pain, while opioid analgesics are considered effective for 
managing severe chronic pain that is difficult to control 
using nonopioid therapies.8,9) Indeed, the use of opioids for 
chronic non-cancer pain, such as back pain, spinal osteo-
arthritis, and failed back surgery, has increased in recent 
years.10,11) Recommended pharmacotherapies based on the 
American College of Physicians/American Pain Society 
guidelines12) include acetaminophen, benzodiazepine, 
tramadol, and opioids for both subacute and chronic back 
pain. 
Opioids are considered effective for management of 
nociceptive pain and moderately effective for neuropathic 
pain. However, certain adverse effects, such as constipa-
tion, nausea, and vomiting, can limit the use of opioids in 
clinical practice. Opioid-associated constipation is among 
the most common and bothersome of these adverse ef-
fects, and can reduce QoL for patients.13) A prolonged-
release (PR) formulation combining oxycodone, an opioid 
analgesic, with naloxone, a peripherally acting opioid 
antagonist, is associated with a lower incidence of con-
stipation than oxycodone alone.14-16) Naloxone binds to 
µ opioid receptors in the gut wall with an affinity higher 
than that of oxycodone, thereby preventing oxycodone 
from exerting an effect on the gastrointestinal system, and 
reducing the risk of constipation. Owing to its low oral 
bioavailability, naloxone has no effect on opioid receptors 
in the central nervous system and therefore does not affect 
the analgesic properties of oxycodone.17) 
In Korea, use of opioids has increased markedly 
because of heightened awareness of the need for adequate 
pain control on the part of both physicians and pa-
tients.10,18,19) This trend has been studied widely in the con-
text of cancer pain, but few studies have included patients 
with non-cancer pain. A PR formulation of oxycodone/
naloxone was approved in Korea in 2009 for the man-
agement of chronic moderate to severe cancer pain and 
non-cancer pain. Although there are extensive data from 
clinical trials of oxycodone/naloxone in European popula-
tions,14-16) no clinical data exist for its use in Korean pa-
tients. The objective of the present study was to assess the 
efficacy and safety of PR oxycodone/naloxone in Korean 
patients with chronic moderate to severe pain attributable 
to a spinal disorder, that was not adequately controlled 
with weak opioids and/or nonsteroidal anti-inflammatory 
drugs (NSAIDs).
METHODS
Study Design and Patients 
This study was an 8-week, single-arm, open-label, inter-
ventional, phase IV trial conducted in 10 centers in Korea 
between 26 September, 2012 and 2 August, 2013 (Clini-
calTrials.gov identifier: NCT01811238). An Institutional 
Review Board at each site approved the study, which was 
performed in accordance with the Declaration of Helsinki, 
the International Conference on Harmonisation, and Ko-
rean Good Clinical Practice guidelines. Written informed 
consent was obtained from all patients before participa-
tion. 
Korean adults aged ≥ 20 to < 80 years were eligible 
for inclusion in the study if they had experienced chronic 
moderate to severe pain (pain score ≥ 4 on a numeric 
rating scale [NRS] ranging from 0 [no pain] to 10 [very 
severe pain]) from a spinal disorder for at least 3 months 
that was not satisfactorily controlled with analgesics (weak 
opioids or NSAIDs). Patients were either opioid-naïve or 
had not received strong opioid treatment (including oxy-
codone/naloxone) within 4 weeks of screening.
Key exclusion criteria were: pain with a nonspinal 
cause; major surgery within 1 month of screening or 
planned surgery during the study period; uncontrolled 
constipation; severe respiratory depression due to hypoxia 
and/or hypercapnia; moderate to severe hepatic impair-
ment; and clinically significant impairment of cardiovas-
cular, respiratory, or renal function. Patients were also 
excluded if they were receiving anticancer treatment for 
nonmalignant or malignant tumours, or any treatment 
that could affect pain measurements.
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Interventions
Patients received oxycodone/naloxone (Targin; Mundi-
pharma Korea Ltd., Seoul, Korea) PR tablets at a starting 
dose of 5/2.5 mg administered twice daily for 8 weeks. The 
dose could be uptitrated to 10/5 mg, 20/10 mg, or 40/20 
mg twice daily at the discretion of the investigator. The cri-
teria for uptitration were as follows: use of analgesic rescue 
medication (immediate-release oxycodone hydrochloride 
5 mg) on average ≥ 2 times per day (i.e., ≥ 10 mg/day); 
worsening NRS pain score compared with the previous 
visit; or any other reason considered appropriate by the 
investigator. 
Analgesics used continuously and at a stable dose 
prior to the study were permitted as concomitant medi-
cations if the investigator deemed that these would not 
affect the study results. If patients were receiving medica-
tions that could induce additional central nervous system 
depression when taken with oxycodone/naloxone (e.g., 
opioid antagonists, hypnotics, or central nervous sys-
tem depressants), they had to be assessed and could be 
withdrawn from the study at the investigator’s discretion. 
Prescription of laxatives was permitted as required during 
the study. Strong opioids (e.g., buprenorphine, morphine) 
and new prescriptions of analgesics (other than the study 
drugs) were not permitted during the study. 
Outcome Measures
Efficacy
The primary outcome was the change in pain intensity 
as measured on the NRS between baseline and week 8 of 
treatment. Patients were asked to rate their average pain 
intensity score over the 24 hours prior to the visit. Inves-
tigators provided assessments of overall satisfaction with 
treatment at baseline and weeks 1, 4, and 8. 
Secondary outcomes included the change from 
baseline in pain intensity score at week 4 of treatment 
and the change from baseline in QoL, measured using a 
Korean language version of the EuroQol-five dimensions 
questionnaire (EQ-5D)20,21) and the EQ-visual analogue 
scale (EQ-VAS) at week 8 of treatment. The EQ-5D cov-
ers the domains of mobility, self-care, usual activity, pain/
discomfort, and anxiety/depression, with each item being 
scored on a 3-point scale from 1 (no problems) to 3 (in-
ability/extreme problems). The EQ-VAS enables patients 
to rate their overall health status on the day of each visit on 
a scale from 0 (worst imaginable) to 100 (best imaginable). 
Safety
Safety assessments included reports at any time (including 
during each study visit) of adverse events, serious adverse 
events, and adverse drug reactions, defined as reactions for 
which a causal relationship with the study drug could not 
240 Enrolled
159 Completed study
220 Safety set
209 ITT set
120 Per-protocol set
5 Failed screening
1 Withdrew informed consent
1 Lost to follow-up
3 Others
20 Excluded from safety set
20 Study drug not administered
11 Excluded from ITT set
5 Primary efficacy assessment not performed
6 Violation of inclusion/exclusion criteria
81 Dropped out
2 Serious adverse event
23 Nonserious adverse event
4 Protocol violation
42 Withdrew informed consent
4 Pain control failure
6 Others
245 Assessed for eligibility
Fig. 1. Patient disposition. ITT: intention-
to-treat.
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be ruled out. Clinical laboratory tests were performed at 
baseline and at week 8. A physical examination including 
measurement of vital signs was performed at baseline and 
at weeks 2, 4, and 8.
Statistical Analyses
Efficacy data were analysed in the intention-to-treat (ITT) 
and per-protocol (PP) sets. The ITT set included patients 
who had received ≥ 1 dose of study drug and had data 
available for ≥ 1 primary efficacy endpoint. The PP set 
included patients in the ITT set who had completed the 
study according to the protocol. Paired t-tests were used 
to analyse changes in the NRS score from baseline to week 
8 (primary outcome) or week 4 (secondary outcome) and 
differences between baseline and week 8 in the EQ-5D to-
tal score.
The safety set included all patients who received at 
least one dose of study drug. Changes in clinical labora-
tory tests and vital signs between baseline and week 8 were 
analysed using paired t-tests. Changes in clinical laborato-
ry test results and findings on physical examination from 
baseline to week 8 were summarized by frequency and 
percentage, and the predose and postdose measurements 
were compared using McNemar’s test. The last observa-
tion carried forward method was used for missing data or 
patients withdrawn during the study. 
Sample Size
Based on data from a previous study of patients with low 
back pain or osteoarthritis pain,22) the sample size needed 
to achieve a significance level of 0.05 for the primary end-
point was 189 patients. Assuming a 20% dropout rate, the 
aim was to enroll 237 patients into the study.
RESULTS
Baseline Characteristics 
Of the 240 patients enrolled, 220 were included in the 
safety set and 209 in the ITT set (Fig. 1). The mean ± 
standard deviation (SD) patient age in the safety set was 
62.3 ± 10.4 years, and 61.8% of the patients were female 
(Table 1). The study included patients with persistent or 
unresolved pain for ≥ 3 months from spinal disorders 
including (but not limited to) lumbar disc herniation, 
spinal stenosis, spondylolisthesis, internal disc disruption, 
cervical disc herniation, cervical myelopathy, osteoporotic 
vertebral fracture, persistent postoperative back pain, spi-
nal fracture, degenerative disc disease, spinal deformity, 
and spinal cord injury. In these patients, the pain caused 
by the original condition did not resolve and resulted in 
persistent pain; therefore, they were considered eligible for 
the study. Eighty-three patients (37.7%) had a history of 
surgery within 3 years of the start of the study; 53 of these 
patients (24.1%) had a history of surgery related to a spinal 
disorder.
All patients in the safety set had a history of receiv-
ing analgesic medication within 3 months of the screening 
visit (Table 1). The majority of patients (n = 141, 64.1%) 
had previously used opioids. Most patients (n = 138, 
62.7%) continued to take concomitant permitted analge-
sics (Table 1).
Oxycodone/Naloxone Dose and Use of Analgesic Rescue 
Medication
Among the 220 patients in the safety set, the daily dose of 
PR oxycodone/naloxone at week 8 was (mean ± SD, 18.2 
± 10.2 mg). For the 159 patients who completed the study, 
the dose of PR oxycodone/naloxone at the final visit was 
10/5 mg twice daily for 68 patients (42.8%), 5/2.5 mg twice 
daily for 67 patients (42.1%), 20/10 mg twice daily for 23 
Table 1.  Baseline Demographics, Patient Characteristics, and 
Medication Use (Safety Set)
Characteristic Value (n = 220)
Sex
   Male  84 (38.2)
   Female 136 (61.8)
Age (yr) 62.3 ± 10.4
Analgesic history within 3 months of screening 220 (100)
   Weak opioid 138 (62.7)
   NSAID 129 (58.6)
   Adjuvant analgesic  77 (35.0)
   Strong opioid  3 (1.4)
Concomitant analgesic* 138 (62.7)
   Weak opioid  79 (35.9)
   NSAID  90 (40.9)
   Adjuvant analgesic  58 (25.4)
Values are presented as number (%) or mean ± standard deviation. 
NSAID: nonsteroidal anti-inflammatory drug.
*Patients were permitted to administer ongoing analgesic therapy (NSAIDs, 
weak opioids and/or adjuvant analgesics) at prestudy doses during the study; 
ongoing analgesics had been started before participation in the study and 
were being used at the time of screening at a stable dose. Two patients (0.9%) 
treated with concomitant strong opioids were excluded from the per-protocol 
set for analysis. 
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patients (14.5%), and 40/20 mg twice daily for one patient 
(0.6%). During the study, 124 patients (56.4%) in the safety 
set required at least one dose of analgesic rescue medica-
tion.
Efficacy 
Pain
In the ITT set, the overall mean NRS pain score decreased 
significantly from 6.5 ± 1.4 at baseline to 4.8 ± 2.0 at week 
8 (mean ± SD difference, –1.7 ± 2.2; –25.9%; p < 0.0001) 
(Fig. 2). The reduction in NRS pain score from baseline 
to week 4 was also statistically significant (mean ± SD 
change, –1.3 ± 2.0; –20.9%; p < 0.0001) (Fig. 2).
In an analysis of NRS scores in the PP set, the mean 
score was 6.6 ± 1.4 at baseline and 4.4 ± 2.0 at week 8, rep-
resenting a change of –2.2 ± 1.9 (33.7%, p < 0.0001); the 
reduction was statistically significant and greater than that 
in the ITT set.
Quality of life 
In the ITT set, there was a 37.5% improvement in the 
mean EQ-5D score (an increase of 0.2 ± 0.4) from baseline 
to week 8, which was highly significant (p < 0.0001) (Fig. 
3A). Assessment of health status on the day of each visit, 
measured using the EQ-VAS, also demonstrated a signifi-
cant improvement from baseline to week 8 (p < 0.0001) 
(Fig. 3B).
Analysis of EQ-5D scores in the PP set demon-
strated a mean change from baseline to week 8 of 0.2 ± 0.4, 
representing an increase of 52.5% (p < 0.0001). In the PP 
set, the mean change in EQ-VAS score from baseline to 
week 8 was 13.9 ± 23.0 (27.2%, p < 0.0001).
Safety 
In the safety set, a total of 120 adverse events were re-
ported in 77 patients (35.0%); 95 of these events, reported 
in 61 patients (27.7%), were deemed to be adverse drug 
reactions, the most common of which were nausea (9.1%), 
dizziness (5.5%), and constipation (5.5%) (Table 2). The 
majority of adverse events occurred within 1 week of treat-
ment with the study drug. Forty-four adverse events were 
reported in 30 patients (13.6%) and 38 adverse drug reac-
tions were reported in 26 patients (11.8%). 
One unexpected adverse drug reaction (mild pol-
lakiuria) was reported; this did not warrant a change in the 
dose of the study drug and resolved after 1 month. Most 
of the adverse drug reactions were mild (72 events, 75.8%) 
and had resolved (54.7%) or were resolving (23.2%) at the 
Fig. 2. The plot shows mean pain intensity score (numeric rating scale 
[NRS]) at baseline and at weeks 4 and 8. The values shown in each bar 
represent the mean ± standard deviation score. *Statistically significant 
changes in pain intensity scores were observed after treatment with the 
study drug. 
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Fig. 3. The plot shows mean scores at baseline and at week 8 for EuroQol-five dimensions questionnaire (EQ-5D, A) and EQ-visual analogue scale (EQ-
VAS, B). The values shown in each bar represent the mean ± standard deviation score. 
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end of the study period. 
Three serious adverse events (fracture of the femur, 
osteoarthritis, and renal cancer) occurred in three patients 
(1.4%), but no causal relationship with the study drug was 
found. Twenty-three patients (10.5%) withdrew from the 
study because of adverse drug events; 36 events occurred 
in these patients. No clinically significant changes in clini-
cal laboratory and blood chemistry tests or vital signs were 
observed.
DISCUSSION
To our knowledge, this study is the first in a Korean 
population to demonstrate the efficacy and safety of PR 
oxycodone/naloxone in the treatment of chronic moderate 
to severe pain associated with a spinal disorder and unsat-
isfactorily controlled by weak opioids and NSAIDs. Over 
8 weeks of treatment, PR oxycodone/naloxone effectively 
reduced pain intensity, improved QoL, and was well toler-
ated in these patients.
Our study found a statistically significant reduc-
tion in mean pain intensity score of 1.7 points, represent-
ing a decrease of almost 26% after 8 weeks of treatment 
with PR oxycodone/naloxone (ITT set). This reduction 
of 1.7 points on the NRS for pain intensity corresponds 
to “much improved” or “very much improved” pain, and 
reductions in pain intensity of 10%–20% are considered 
to reflect minimally important changes.23,24) The reduction 
in pain intensity score was greater in patients in the PP set 
(2.2 points, representing a 34% decrease). Analysis of the 
clinical importance of changes in pain intensity in a group 
of patients with chronic non-cancer pain (mean baseline 
NRS score 5.9) treated for 12 weeks with duloxetine indi-
cated that a reduction of 34% in pain intensity score was 
clinically important.25) However, the magnitude of clinical-
ly important change in pain intensity may differ between 
the individual patient level and the group level, and should 
be considered alongside the other benefits of treatment, 
such as tolerability.23)
Of note in our study was the effective pain control 
achieved using relatively low doses of oxycodone/nalox-
one; the majority of patients received the lowest dosage 
of 10/5 mg/day or the second lowest dosage of 20/10 mg/
day. In this regard, the present formulation of oxycodone/
naloxone offers a new low-dose option for Korean patients 
and may be particularly useful when starting therapy. 
Quality of life, measured using the EQ-5D, im-
proved by almost 38% over the 8 weeks of treatment with 
oxycodone/naloxone, while patients’ health status on the 
day of each study visit, measured using the EQ-VAS, im-
proved significantly by almost 22% over the same period. 
Although the prespecified analysis in our study only in-
cluded overall QoL assessment, it would also be clinically 
meaningful to explore which dimensions of QoL were 
most improved. Our findings are consistent with those of 
a previous study in which patients treated with oxycodone 
alone were switched to oxycodone/naloxone because of 
symptoms of opioid-induced constipation. After 12 weeks 
of treatment, patients experienced a significant improve-
ment in QoL.26) 
Of the 220 patients in our study who received at 
least one dose of oxycodone/naloxone, almost 28% re-
ported adverse drug reactions, the most common of which 
were nausea, dizziness, constipation, and pruritus. There 
was one unexpected adverse drug reaction, i.e., pollaki-
uria. Constipation is the most common opioid-induced 
adverse event reported in patients receiving chronic opioid 
treatment and negatively impacts overall health-related 
QoL.13) In our study, 5.5% of patients reported constipa-
tion, which is much lower than the rate of ≥ 15% reported 
for chronic opioid use in literature reviews and meta-anal-
yses.27-29) The incidence of constipation in a randomized 
Table 2.  Adverse Events and Adverse Drug Reactions Reported 
During the Study (Safety Set)
Event Value (n = 220)
Any adverse event  77 (35.0)
Serious adverse event  3 (1.4)
Withdrawal due to adverse event  23 (10.5)
Adverse drug reaction*  61 (27.7)
   Nausea 20 (9.1)
   Constipation 12 (5.5)
   Dizziness 12 (5.5)
   Pruritus 10 (4.6)
   Somnolence  6 (2.7)
   Vomiting  5 (2.3)
   Decreased appetite  5 (2.3)
   Headache  4 (1.8)
   Upper abdominal pain  3 (1.4)
Serious adverse drug reaction 0
Withdrawal due to adverse drug reaction  23 (10.5)
Values are presented as number (%). 
*Reported in ≥ 1% of patients.
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placebo-controlled and active-controlled study of oxyco-
done/naloxone was 8.4%,16) somewhat higher than in our 
study. We note that these observations, which were based 
on adverse events reporting in our study, do not permit 
direct conclusions to be made about reduction or preven-
tion of constipation with oxycodone/naloxone. To directly 
address constipation, it would be desirable to perform a 
parallel-group comparison of oxycodone/naloxone with 
oxycodone alone, and to assess constipation symptoms us-
ing a specific tool.
As this was a single-arm study without a placebo 
or active-control group, care should be taken when inter-
preting the degree of improvement attributable to the test 
treatment. Another limitation of the present study was its 
short duration, which precluded assessment of the longer-
term efficacy and safety of oxycodone/naloxone in this 
population. 
In this study, Korean patients with chronic pain 
from spinal disorders receiving a PR oral formulation of 
oxycodone/naloxone twice daily had statistically signifi-
cant and clinically relevant reductions in pain intensity 
and experienced improved QoL after 8 weeks of treatment. 
Furthermore, PR oxycodone/naloxone demonstrated a 
favourable safety profile in these patients, with few re-
quirements for dose reduction because of adverse drug re-
actions, including gastrointestinal effects. PR oxycodone/
naloxone may be particularly useful for patients with or 
at risk of bowel dysfunction who require effective pain 
control.30) Consequently, PR oxycodone/naloxone may im-
prove the acceptability of opioid analgesics as a treatment 
for chronic non-cancer pain.
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